Full Text View
Tabular View
Study Results
Related Studies
Olanzapine Treatment of Patients With Bipolar I Disorder
This study has been completed.

First Received on July 30, 2007.   Last Updated on April 26, 2011   History of Changes
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00510146
  Purpose

The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.


Condition Intervention Phase
Depression, Bipolar
 Drug: Olanzapine
Drug: Placebo
 Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo

Resource links provided by NLM:

MedlinePlus related topics: Depression Mental Disorders Psychotic Disorders
Drug Information available for: Olanzapine
U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: No ]
    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).


Secondary Outcome Measures:
  • Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  • Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase) [ Time Frame: Baseline through Endpoint (Week 6) ] [ Designated as safety issue: No ]
    Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  • Change From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: No ]
    CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).

  • Percentage of Participants With Recovery (Acute Phase) [ Time Frame: Baseline through Endpoint (Week 6 ) ] [ Designated as safety issue: No ]
    Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  • Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: No ]
    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

  • Change From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: No ]
    The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

  • Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.

  • Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.

  • Percentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.

  • Percentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.

  • Percentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: No ]
    In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.

  • Percentage of Participants With Emergence of Mania During the Study (Acute Phase) [ Time Frame: Baseline through Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
    Emergence of mania is defined as first occurrence of score of >=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

  • Percentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase) [ Time Frame: Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
    EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not >=3 on 1 item nor >=2 on 2 items; abnormal endpoint is defined as a score >=3 on 1 item or >=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score <2; abnormal endpoint is a score >=2 or an increase >= 2 from that baseline score.

  • Change From Baseline to Endpoint in Blood Pressure (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Weight (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Albumin (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Erythrocyte Count (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Hematocrit (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Hemoglobin A1c (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Hemoglobin (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Prolactin (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
    Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

  • Change From Baseline to Endpoint in Heart Rate (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase) [ Time Frame: Baseline, Endpoint (Week 6) ] [ Designated as safety issue: Yes ]
    The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.

  • Number of Participants With Adverse Events (Acute Phase) [ Time Frame: Baseline through Week 6 (Acute Phase) ] [ Designated as safety issue: Yes ]
    Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.

  • Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24) ] [ Designated as safety issue: No ]
    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.

  • Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24) ] [ Designated as safety issue: No ]
    Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  • Percentage of Participants With Recovery (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24) ] [ Designated as safety issue: No ]
    Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  • Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: No ]
    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

  • Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
    Emergence of mania is defined as first occurrence of score of >=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

  • Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase) [ Time Frame: Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
    EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not >=3 on 1 item nor >=2 on 2 items; abnormal endpoint is defined as a score >=3 on 1 item or >=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score <2; abnormal endpoint is a score >=2 or an increase >= 2 from that baseline score.

  • Change From Baseline to Endpoint in Blood Pressure (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Weight (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/ Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Chloride (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Creatinine (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Platelet Count (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Prolactin (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Uric Acid (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Change From Baseline to Endpoint in ECG (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
    Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

  • Change From Baseline to Endpoint in Heart Rate (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
  • Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase) [ Time Frame: Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
    The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (>=17).

  • Number of Participants With Adverse Events (Open-Label Phase) [ Time Frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24) ] [ Designated as safety issue: Yes ]
    Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.


Enrollment: 514
Study Start Date: August 2007
Study Completion Date: July 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Olanzapine
During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
 Drug: Olanzapine
5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
Other Names:
  • LY170053
  • Zyprexa
Placebo Comparator: Placebo
Matching placebo administered once daily, by mouth during double-blind treatment.
 Drug: Placebo
placebo tablets, oral, once daily at bedtime, 6 weeks
Experimental: Olanzapine (open-label treatment period)
During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
 Drug: Olanzapine
5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
Other Names:
  • LY170053
  • Zyprexa

Detailed Description:
  1. Dose range and administration mode: Oral Olanzapine 5mg - 20mg/day

  2. Duration:

    1. Screening phase is 2-28 days.
    2. Double-blind treatment phase is 6 weeks
    3. Open-label extension phase is 18 weeks
  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided informed consent
  • All female patients must test negative for pregnancy and females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug
  • Patients must fulfill the criteria for a major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) as well as criteria for bipolar I disorder, depressed, as defined in the DSM-IV-TR, based on clinical assessment and confirmed by the structured diagnostic interview, the Mini International Neuropsychiatric Interview (MINI), at study entry
  • Patients must have a current 17-item Hamilton Depression Rating Scale (HAMD-17) score greater than or equal to 18 at Visit 1 and Visit 2
  • Patients must have a current Young Mania Rating Scale (YMRS) total score less than or equal to 8 at Visit 2.

Exclusion Criteria:

  • Has received treatment within the past 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry
  • Has participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) before study entry
  • Was previously treated with olanzapine and had bipolar depression considered to be treatment-resistant to olanzapine or to olanzapine in combination with an available selective serotonin reuptake inhibitor (SSRI)
  • Is experiencing (at the time of study entry) a current episode of bipolar depression that is greater than 90 days in duration
  • Has been treatment-resistant to any therapy prescribed for bipolar depression when olanzapine alone or with an SSRI prescribed at an appropriate dose and duration
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00510146

Locations
China
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beijing, China, 100088
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Changsha, China, 410008
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chengdu, China, 610041
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Guang Zhou, China, 510370
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hangzhou, China, 310003
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Harbin, China, 150001
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kunming, China, 650032
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nanjing, China, 210029
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Shanghai, China, 200030
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wu Han, China, 430060
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Xi'An, China, 710032
Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hiroshima, Japan, 731-0501
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Shiga, Japan, 525-0037
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tokyo, Japan, 170-0002
Korea, Republic of
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Seongnam-Si, Korea, Republic of, 463-707
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5hrs, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT00510146     History of Changes
Other Study ID Numbers: 11218, F1D-MC-HGMP
Study First Received: July 30, 2007
Results First Received: February 15, 2011
Last Updated: April 26, 2011
Health Authority: United States: Food and Drug Administration;   Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Bipolar Disorder
Depression
Depressive Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Behavioral Symptoms
Olanzapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
 Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on February 09, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services